Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at HC Wainwright

HC Wainwright upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT) to a strong-buy rating in a report published on Friday morning,Zacks.com reports.

Several other research firms have also weighed in on IKT. Wall Street Zen raised shares of Inhibikase Therapeutics to a “sell” rating in a report on Saturday. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, December 1st. Cantor Fitzgerald raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Three investment analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Inhibikase Therapeutics currently has a consensus rating of “Buy”.

Inhibikase Therapeutics Stock Performance

IKT stock opened at $2.00 on Friday. Inhibikase Therapeutics has a 1-year low of $1.33 and a 1-year high of $3.49. The firm has a 50 day moving average of $1.56. The company has a market cap of $150.36 million, a price-to-earnings ratio of -5.13 and a beta of 0.88.

Inhibikase Therapeutics (NASDAQ:IKT) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.13) EPS for the quarter.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.